ATHENS, GA / ACCESS Newswire / October 13, 2025 / NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a leader in health and wellness solutions, today announced that its wholly owned subsidiary, Good Saltâ"¢ Life, Inc., has deployed its advanced ByoCartâ"¢ Disinfection System at Baptist Hospital, the flagship facility of Baptist Health. The ByoCart system will enhance Baptist Hospital's infection prevention and environmental safety protocols by improving both surface disinfection and air quality throughout patient ca ...

Health systems from Tennessee to Texas are training more high-school students to work in healthcare fields https://t.co/28f2ZoRvbX ...

Hospitals are training more high-school students to work in healthcare fields https://t.co/dYgPcEeFXO ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by Agilon Health's announcement that it is suspending its previously issued full-year 2025 financial guidance and related assumptions, indicating that industry headwinds are more acute than expected [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Insights - Universal Health Services, Inc. (UHS) is a significant player in the U.S. healthcare sector, operating a network of acute care hospitals, behavioral health facilities, and ambulatory centers, competing with major companies like HCA Healthcare and Tenet Healthcare [1] Performance Summary - UHS has experienced a 30-day gain of 3.38%, indicating strong investor confidence and positive market sentiment, despite a recent 1.91% decline over the last 10 days, which may present a buying opportunity for investors [2][6] - The stock is projected to appreciate by 14.75%, supported by UHS's strategic positioning and strong fundamentals within the healthcare sector, making it an appealing option for growth-oriented investors [3][6] Financial Health - UHS's financial health is highlighted by a Piotroski Score of 8, reflecting strong profitability and efficient operations, which is essential for sustaining growth and delivering shareholder value [4] - Analysts have set a target price of $226.33 for UHS, indicating substantial upside potential from current levels, with recent price movements suggesting a potential support level, making it an attractive entry point for investors [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - The investigation follows a significant stock price drop of 51.5% on August 5, 2025, after Agilon Health suspended its full-year 2025 financial guidance, citing more acute industry headwinds than previously expected [3]. Group 2: Company Performance and Financial Guidance - On August 4, 2025, Agilon Health reported its second-quarter results and indicated that it was suspending its previously issued financial guidance for the full year 2025 [3].

Market Overview - The S&P 500 dropped 0.28% to 6,735.11, the Nasdaq slipped 0.08% to 23,024.63, and the Dow fell 243.36 points, or 0.52%, closing at 46,358.42 due to concerns over the ongoing U.S. government shutdown [1] - Investors are closely monitoring the potential impacts of the shutdown on economic activity and corporate results, leading to a cautious market sentiment [1] Value Investing Insights - The Price to Cash Flow (P/CF) ratio is highlighted as an effective valuation metric for assessing value stocks, with a lower P/CF indicating better value and strong cash generation potential [2][3] - Analysts emphasize that cash flow is a more reliable indicator of a company's financial health compared to earnings, which can be subject to manipulation [4] Selection Criteria for Value Stocks - Parameters for selecting true-value stocks include: - P/CF less than or equal to the industry median - Price greater than or equal to $5 - Average 20-Day Volume greater than 100,000 - P/E using (F1) less than or equal to the industry median [7][8] - Additional metrics include P/B, P/S, PEG ratios, and Zacks Rank to avoid value traps and identify stocks with strong upside potential [6][10] Featured Value Stocks - StoneCo Ltd. (STNE) has a trailing four-quarter earnings surprise of 11.5% and a Value Score of B, with expected sales and EPS growth of 9.8% and 20% respectively [12][11] - Integer Holdings Corporation (ITGR) has a trailing four-quarter earnings surprise of 1.3% and a Value Score of B, with expected sales and EPS growth of 7.8% and 20.4% respectively [13][12] - Universal Health Services, Inc. (UHS) has a trailing four-quarter earnings surprise of 9.4% and a Value Score of A, with expected sales and EPS growth of 8.5% and 23% respectively [15][14] - Great Lakes Dredge & Dock Corporation (GLDD) has a trailing four-quarter earnings surprise of 45.3% and a Value Score of A, with expected sales and EPS growth of 9% and 21.4% respectively [16][15]

Core Points - Nutex Health, Inc. is facing a class action lawsuit for investors who purchased securities between August 8, 2024, and August 14, 2025, with a deadline to file a lead plaintiff motion by October 21, 2025 [1] - Blue Orca Capital issued a short report on July 22, 2025, alleging that Nutex is exposed to litigation risk due to its association with HaloMD, which is involved in a fraudulent scheme against insurance companies [3] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, or 10.05%, closing at $100.01 per share on the same day [3] Legal Representation - The Portnoy Law Firm is representing investors in claims related to corporate misconduct and offers complimentary case evaluations [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for investors in the past [4]

Core Insights - UnitedHealth Group's affiliate, Atrius Health, plans to acquire Acton Medical Associates, a primary care group in the Boston area, which will enhance patient access to care and resources [1][2][3] - The acquisition indicates that Optum, UnitedHealth's division, is continuing its expansion despite recent earnings challenges [3][4] - Optum has experienced a 7% year-over-year revenue decrease in Q2, attributed to legacy customer contract revisions and Medicare Advantage funding cuts [5] Company Developments - Atrius Health will provide Acton's patients with continued access to their providers while offering additional resources and administrative support [3] - The acquisition is part of Optum's strategy to improve health system performance through analytics and technology [4] - UnitedHealth Group is under investigation by the Justice Department regarding potential Medicare fraud and business practices at Optum Rx [5][6]

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].